{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:42Z","timestamp":1793316582138,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41571-024-00945-4","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:02:22Z","timestamp":1727787742000},"page":"771-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Two decades of advances in clinical oncology \u2014 lessons learned and future directions"],"prefix":"10.1038","volume":"21","author":[{"given":"Susana","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-9061","authenticated-orcid":false,"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-9625","authenticated-orcid":false,"given":"Luca","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-2667","authenticated-orcid":false,"given":"Josep M.","family":"Llovet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-2772","authenticated-orcid":false,"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2384-9475","authenticated-orcid":false,"given":"Kathy","family":"Pritchard-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6791-9324","authenticated-orcid":false,"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph R.","family":"Weichselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"945_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3322\/caac.21818","volume":"74","author":"G Kroemer","year":"2024","unstructured":"Kroemer, G., Chan, T. A., Eggermont, A. M. M. & Galluzzi, L. Immunosurveillance in clinical cancer management. CA Cancer J. Clin. 74, 187\u2013202 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"945_CR2","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205\u20132218 (2013).","journal-title":"J. Clin. Oncol."},{"key":"945_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"945_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2402604 (2024).","journal-title":"N. Engl. J. Med."},{"key":"945_CR6","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1200\/JCO.22.02575","volume":"41","author":"GV Long","year":"2023","unstructured":"Long, G. V., Menzies, A. M. & Scolyer, R. A. Neoadjuvant checkpoint immunotherapy and melanoma: the time is now. J. Clin. Oncol. 41, 3236\u20133248 (2023).","journal-title":"J. Clin. Oncol."},{"key":"945_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ccell.2024.04.005","volume":"42","author":"SY Liu","year":"2024","unstructured":"Liu, S. Y., Feng, W. N. & Wu, Y. L. Immunotherapy in resectable NSCLC: answering the question or questioning the answer? Cancer Cell. 42, 727\u2013731 (2024).","journal-title":"Cancer Cell."},{"key":"945_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","volume":"16","author":"SYM Liu","year":"2023","unstructured":"Liu, S. Y. M. et al. Emerging evidence and treatment paradigm of non-small cell lung cancer. J. Hematol. Oncol. 16, 40 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"945_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"945_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"945_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327, 464\u2013477 (2022).","journal-title":"JAMA"},{"key":"945_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100\u2013113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie, S. A. & Hill, G. R. Immunotherapy of multiple myeloma. J. Clin. Invest. 130, 1565\u20131575 (2020).","journal-title":"J. Clin. Invest."},{"key":"945_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ncponc0476","volume":"3","author":"JE Dowell","year":"2006","unstructured":"Dowell, J. E. & Minna, J. D. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nat. Clin. Pract. Oncol. 3, 170\u2013171 (2006).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"945_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617\u2013628 (2019).","journal-title":"N. Engl. J. Med."},{"key":"945_CR16","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda, N. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 376, 2147\u20132159 (2017).","journal-title":"N. Engl. J. Med."},{"key":"945_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith, I. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 21, 1443\u20131454 (2020).","journal-title":"Lancet Oncol."},{"key":"945_CR18","unstructured":"International Agency for Research on Cancer. Global Burden of Gastrointestinal Cancers https:\/\/gco.iarc.fr\/stories\/gastro-intestinal\/en (2024)."},{"key":"945_CR19","unstructured":"Colorectal Cancer Alliance. Young-onset CRC Facts https:\/\/colorectalcancer.org\/resources-support\/community-support\/young-onset-support\/young-onset-crc-facts (2024)."},{"key":"945_CR20","first-page":"PO.17.00029","volume":"2017","author":"W Abida","year":"2017","unstructured":"Abida, W. et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis. Oncol. 2017, PO.17.00029 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"945_CR21","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1158\/1078-0432.CCR-15-0137","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer. Clin. Cancer Res. 22, 1510\u20131519 (2016).","journal-title":"Clin. Cancer Res."},{"key":"945_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161858","volume":"132","author":"SG Zhao","year":"2022","unstructured":"Zhao, S. G. et al. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. Clin. Invest. 132, e161858 (2022).","journal-title":"Clin. Invest."},{"key":"945_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"945_CR24","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"945_CR25","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721\u20131731 (2021).","journal-title":"Lancet Oncol."},{"key":"945_CR26","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1002\/cncr.35417","volume":"130","author":"S Banerjee","year":"2024","unstructured":"Banerjee, S. & Hasson, S. P. Top advances of the year: immunotherapy in endometrial cancer. Cancer 130, 3082\u20133086 (2024).","journal-title":"Cancer"},{"key":"945_CR27","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore, K. N. et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N. Engl. J. Med. 389, 2162\u20132174 (2023).","journal-title":"N. Engl. J. Med."},{"key":"945_CR28","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos, J. P. et al.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200\u20131210 (2004).","journal-title":"N. Engl. J. Med."},{"key":"945_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh, P. et al. European Study Group for Pancreatic Cancer. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm multicentre randomised phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 157\u2013168 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"945_CR30","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology 23, 1231\u20131251 (2021).","journal-title":"Neuro-Oncology"},{"key":"945_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170\u2013186 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/2159-8290.CD-21-1094","volume":"12","author":"SM Pfister","year":"2022","unstructured":"Pfister, S. M. et al. A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era. Cancer Discov. 12, 331\u2013355 (2022).","journal-title":"Cancer Discov."},{"key":"945_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jnci\/djad239","volume":"116","author":"ADJ Pearson","year":"2024","unstructured":"Pearson, A. D. J. et al. Impact of ACCELERATE paediatric strategy forums: a review of the value of multi-stakeholder meetings in oncology drug development. J. Natl Cancer Inst. 116, 200\u2013207 (2024).","journal-title":"J. Natl Cancer Inst."},{"key":"945_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8\u201310 (1995).","journal-title":"J. Clin. Oncol."},{"key":"945_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","volume":"19","author":"RR Katipally","year":"2022","unstructured":"Katipally, R. R., Pitroda, S. P., Juloori, A., Chmura, S. J. & Weichselbaum, R. R. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat. Rev. Clin. Oncol. 19, 585\u2013599 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR36","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel, K. & Alix-Panabi\u00e8res, C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med. 16, 398\u2013406 (2010).","journal-title":"Trends Mol. Med."},{"key":"945_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","volume":"20","author":"R Lawrence","year":"2023","unstructured":"Lawrence, R. et al. Circulating tumour cells for early detection of clinically relevant cancer. Nat. Rev. Clin. Oncol. 20, 487\u2013500 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR38","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S1470-2045(18)30415-7","volume":"19","author":"S Kaasa","year":"2018","unstructured":"Kaasa, S. et al. Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol. 19, e588\u2013e653 (2018).","journal-title":"Lancet Oncol."},{"key":"945_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3322\/caac.21490","volume":"68","author":"D Hui","year":"2018","unstructured":"Hui, D., Hannon, B. L., Zimmermann, C. & Bruera, E. Improving patient and caregiver outcomes in oncology: team-based, timely, and targeted palliative care. CA Cancer J. Clin. 68, 356\u2013376 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"945_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrclinonc.2015.201","volume":"13","author":"D Hui","year":"2016","unstructured":"Hui, D. & Bruera, E. Integrating palliative care into the trajectory of cancer care. Nat. Rev. Clin. Oncol. 13, 159\u2013171 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR41","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","volume":"22","author":"A Fundytus","year":"2021","unstructured":"Fundytus, A. et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 22, 1367\u20131377 (2021).","journal-title":"Lancet Oncol."},{"key":"945_CR42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","volume":"7","author":"JC Del Paggio","year":"2021","unstructured":"Del Paggio, J. C. et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 7, 728\u2013734 (2021).","journal-title":"JAMA Oncol."},{"key":"945_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41591-022-02193-4","volume":"29","author":"G Kroemer","year":"2023","unstructured":"Kroemer, G., McQuade, J. L., Merad, M., Andr\u00e9, F. & Zitvogel, L. Bodywide ecological interventions on cancer. Nat. Med. 29, 59\u201374 (2023).","journal-title":"Nat. Med."},{"key":"945_CR44","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.immuni.2024.07.020","volume":"57","author":"L Zitvogel","year":"2024","unstructured":"Zitvogel, L., Fidelle, M. & Kroemer, G. Long-distance microbial mechanisms impacting cancer immunosurveillance. Immunity 57, 2013\u20132029 (2024).","journal-title":"Immunity"},{"key":"945_CR45","doi-asserted-by":"publisher","first-page":"eaaz0868","DOI":"10.1126\/science.aaz0868","volume":"370","author":"HT Nia","year":"2020","unstructured":"Nia, H. T., Munn, L. L. & Jain, R. K. Physical traits of cancer. Science 370, eaaz0868 (2020).","journal-title":"Science"},{"key":"945_CR46","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","volume":"10","author":"S Dong","year":"2024","unstructured":"Dong, S. et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized clinical trial. JAMA Oncol. 10, 932\u2013940 (2024).","journal-title":"JAMA Oncol."},{"key":"945_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.21.01929","volume":"40","author":"B Pellini","year":"2022","unstructured":"Pellini, B. & Chaudhuri, A. A. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J. Clin. Oncol. 40, 567\u2013575 (2022).","journal-title":"J. Clin. Oncol."},{"key":"945_CR48","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41571-023-00733-6","volume":"20","author":"G Harada","year":"2023","unstructured":"Harada, G., Yang, S. R., Cocco, E. & Drilon, A. Rare molecular subtypes of lung cancer. Nat. Rev. Clin. Oncol. 20, 229\u2013249 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","volume":"20","author":"I Otano","year":"2023","unstructured":"Otano, I., Ucero, A. C., Zugazagoitia, J. & Paz-Ares, L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat. Rev. Clin. Oncol. 20, 143\u2013159 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR51","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. 3-Year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 403, 1649\u20131659 (2024).","journal-title":"Lancet"},{"key":"945_CR52","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41571-022-00672-8","volume":"19","author":"T Ugai","year":"2022","unstructured":"Ugai, T. et al. Is early-onset cancer an emerging global epidemic? Current evidence and future applications. Nat. Rev. Clin. Oncol. 19, 656\u2013673 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR53","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet, J. M. et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 21, 294\u2013311 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR54","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.hpb.2017.07.007","volume":"19","author":"T Hackert","year":"2017","unstructured":"Hackert, T. et al. The TRIANGLE operation \u2014 radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB 19, 1001\u20131007 (2017).","journal-title":"HPB"},{"key":"945_CR55","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler, F. et al. Cancer neuroscience: state of the field, emerging directions. Cell 186, 1689\u20131707 (2023).","journal-title":"Cell"},{"key":"945_CR56","unstructured":"Chantada G., Laub T. & Pritchard-Jones K. SIOP\u2019s PARC Program: advancing research capacity for paediatric cancer clinical trials in low resourced countries. Cancer Control 2022 https:\/\/www.cancercontrol.info\/wp-content\/uploads\/2022\/11\/60-65-Chantada.pdf (2022)."},{"key":"945_CR57","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41571-019-0220-6","volume":"16","author":"SP Pitroda","year":"2019","unstructured":"Pitroda, S. P. & Weichselbaum, R. R. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat. Rev. Clin. Oncol. 16, 581\u2013588 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrclinonc.2017.174","volume":"15","author":"K Pantel","year":"2018","unstructured":"Pantel, K. & Hayes, D. F. Disseminated breast tumour cells: biological and clinical meaning. Nat. Rev. Clin. Oncol. 15, 129\u2013131 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"945_CR59","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S1470-2045(23)00319-4","volume":"24","author":"CM Booth","year":"2023","unstructured":"Booth, C. M. et al. Common sense oncology: outcomes that matter. Lancet Oncol. 24, 833\u2013835 (2023).","journal-title":"Lancet Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00945-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00945-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00945-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T13:04:33Z","timestamp":1729515873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00945-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00945-4","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"10 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. has received institutional funding for academic studies from AstraZeneca and GSK; honoraria for lectures from Abbvie, AstraZeneca, GSK, ImmunoGen, Merck Sharpe & Dohme, Mersana, Novacure, Pfizer, Roche, Takeda and Verastem Oncology; has had advisory roles for Abbvie, AstraZeneca, Epsilogen, GSK, Immunogen, ITM Oncologics, Merck Sharpe & Dohme, Mersana, Myriad, Novartis, Oncxerna, Regeneron, Seagen, Shattuck Labs, TORL Biotherapeutics, Verastem Oncology and Zymeworks; received travel support from AstraZeneca, GSK and Verastem Oncology; and is a past Director of Membership at ESMO (2020\u20132022). A.D. has received honoraria from or had advisory roles for 14ner\/Elevation Oncology, Amgen, Anheart Therapeutics, Abbvie, ArcherDX, AstraZeneca, Bayer, Beigene, BergenBio, Blueprint Medicines, Boundless Bio, Bristol Myers Squibb, Chugai Pharmaceutical, EcoR1, EMD Serono, Entos, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta\/Genentech\/Roche, Innocare, Janssen, Loxo\/Lilly, Merus, Monopteros, MonteRosa, Novartis, Nuvalent, Pfizer, Prelude, Regeneron, Repare RX, Takeda\/Ariad\/Millenium, Treeline Bio, TP Therapeutics, Tyra Biosciences, Verastem Oncology and Zymeworks; has received institutional funding from Foundation Medicine, GSK, Pharmamar, Taiho and Teva; owns equity in mBrace and Treeline; has a copyright for selpercatinib-osimertinib (pending, US 18\/041,617); has received royalties from UpToDate and Wolters Kluwer; has received support for food\/beverage from Boehringer Ingelheim, Merck and Puma; and has received continuing medical education-related honoraria from Answers in CME, Applied Pharmaceutical Science, AXIS, Clinical Care Options, Doc Congress, EPG Health, Harborside Nexus, I3 Health, Imedex, Liberum, Med Learning, Medendi, Medscape, MedTalks, MJH Life Sciences, MORE Health, Ology, OncLive, Paradigm, Peerview Institute, PeerVoice, Physicians Education Resources, Projects in Knowledge, Resources, Remedica, Research to Practice, RV More, Springer Healthcare, Targeted Oncology, TouchIME and WebMD. T.J.F. has patents in the field of immunotherapy. I.M.G. has had advisory roles for GSK, Janssen, Menarini, Pfizer and Sanofi; and is a co-founder of Predicta bio. L.G. has had advisory roles for Artemida Pharma, AstraZeneca, Beigene, Daiichi-Sankyo, Pfizer, Roche and Zymeworks; has had consulting roles for selected programmes of Amgen, Biomedical Insights, Denali Therapeutics, Menarini, Revolution Medicines, Synaffix and Xymeworks; and is a co-inventor of European Patent Application N. 12195182.6 and 12196177.5 titled \u201cPDL-1 expression in anti-HER2 therapy\u201d with Roche (no compensation provided). R.K.J. has received consultant fees from DynamiCure and SynDevRx; owns equity in Accurius, Enlight and SynDevRx; and has served on the boards of trustees of Tekla Healthcare Investors, Tekla Healthcare Opportunities Fund, Tekla Life Sciences Investors and Tekla World Healthcare Fund; and received grants from Boehringer Ingelheim and Sanofi. G.K. has held research contracts with Daiichi-Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys and Vascage; is on the board of directors of the Bristol Myers Squibb Foundation France; is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio; is in the scientific advisory boards of Hevolution, Institut Servier, Longevity Vision Funds and Rejuveron Life Sciences; and has patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders, of which \u201cMethods for weight reduction\u201d (US11905330B1) is relevant to this study. G.K.\u2019s spouse has held research contracts with 9m, Daiichi-Sankyo, GSK, Incyte, Innovate Pharma, Lytix, Kaleido, Merus, Pilege, Roche, Transgene, and Tusk and Roche; was on the board of directors of Transgene; is a co-founder of everImmune; and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. J.M.L. has received research support from Bayer HealthCare Pharmaceuticals and Eisai; and consulting fees from AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai, Genentech, Glycotest, Merck, Moderna and Roche. G.V.L. is a consultant adviser for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics, IOBiotech, Immunocore, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR, Pierre Fabre, Regeneron, Scancell and SkylineDX. K.P.-J. is the immediate past President of\u00a0the International Society of Paediatric Oncology, chair of the International Society of Paediatric Oncology and WHO non-state actor engagement committee. H.I.S. has been a compensated consultant\/adviser to Bayer, Pfizer, Regeneron Pharmaceuticals, Sanofi (Genzyme Corporation) and WCG Oncology; an uncompensated consultant\/advisory to AIQ Global, Amgen, Janssen Biotech, Janssen Research & Development, LLC and Promontory Therapeutics; has received honoraria from Arsenal Capital and Physician Education Resource; has received reviewer fees from Elsevier; has received institutional research funding from AIQ Solutions, Biodesix, Epic Sciences, Janssen, Prostate Cancer Foundation and Thermo Fisher; holds intellectual property rights at Elucida Oncology; and has received non-financial support from Amgen, Astrin Biosciences, Bayer, Biodesix, Epic Sciences, Promontory Therapeutics, Pfizer, Prostate Cancer Foundation and WCG Oncology. J.T. has had scientific consultancy roles for Alentis Therapeutics, AstraZeneca, Aveo Oncology, Boehringer Ingelheim, Cardiff Oncology, CARSgen Therapeutics, Chugai, Daiichi-Sankyo, F. Hoffmann-La Roche, Genentech, hC Bioscience, Immodulon Therapeutics, Inspirna, Lilly, Menarini, Merck Serono, Merck Sharpe & Dohme, Merus, Mirati, Neophore, Novartis, Ona Therapeutics, Ono Pharma USA, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Takeda Oncology and Tolremo Therapeutics; holds stock at 1TRIALSP, Alentis Therapeutics, Oniria Therapeutics and Pangaea Oncology; and has had educational collaborations with Medscape Education, PeerView Institute for Medical Education and Physicians Education Resource. R.R.W. is a co-founder and Chief Scientific Officer at PersonaDX (USA), which includes start-up stock but no other income. M.W. has received research grants from Novartis, Quercis and Versameb; honoraria for lectures or advisory board participation or consulting from Anheart, Bayer, Curevac, Medac, Neurosense, Novartis, Novocure, Orbus, Pfizer, Philogen, Roche and Servier; and is a board member at the European Organisation for Research and Treatment of Cancer. Y.L.W. has received institutional research support from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Hengrui and Roche; speaker fees from AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Merck Sharp & Dohme, Pfizer, Roche and Sanofi; and has unpaid memberships in governmental organizations of ASCO, ESMO, International Association Study of Lung Cancer, Chinese Society of Clinical Oncology and Chinese Thoracic Oncology Group. C.M.B., E.B., M.W.B. and K.P. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}